Selskabets formål er at drive virksomhed, som omfatter proces- og teknologiudvikling, kontraktproduktion, konsulent- og andre serviceydelser indenfor det bioteknologiske område samt forskning, udvikling og fremstilling af medicinalprodukter, og dermed forbunden virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 2 mia. | -115 mio. | 3.8 mia. | 640 mio. | 1019 | |
CVR: 25950941
Secondary names: CMO BIOTECH A/S, CRO BIOTECH A/S, DOWNSTREAM TECHNOLOGY A/S
Previous names: CMC BIOTECH A/S, CMC BIOPHARMACEUTICALS A/S, CMC BIOLOGICS A/S
2 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
AGC Biologics A/S is currently experiencing financial challenges, as evidenced by a significant decline in profitability, reporting a loss of 115 million DKK in 2024 after a profit of 243.9 million DKK in 2023. Revenue has shown a downward trend, decreasing from 2.5 billion DKK in 2022 to 2.0 billion DKK in 2024. Despite a strong equity position of 640 million DKK, the company's margins have been under pressure, raising concerns about its operational efficiency. Positioned within the pharmaceutical manufacturing industry, AGC Biologics faces the need to reverse its declining trajectory to maintain competitiveness.
AI-generated summary
Yuichiro Tashiro joined the board
Tomoko Miyagawa left the board
Companies in the same industry and area
CVR 24256790
CVR 14605185
CVR 40831622
CVR 39842319
CVR 41407352
companydata.dk